Product Images Alendronate Sodium
View Photos of Packaging, Labels & Appearance
- chemical structure - alendronate 35 mg for teva 1
- IMAGE LABEL - alendronate 35 mg for teva 10
- figure 1 - alendronate 35 mg for teva 2
- figure 2 - alendronate 35 mg for teva 3
- Figure 3 (Top) - alendronate 35 mg for teva 4
- Figure 3 (Bottom) - alendronate 35 mg for teva 5
- Figure 4 (Top) - alendronate 35 mg for teva 6
- Figure 4 (Bottom) - alendronate 35 mg for teva 7
- Figure 5 - alendronate 35 mg for teva 8
- Figure 6 - alendronate 35 mg for teva 9
Product Label Images
The following 10 images provide visual information about the product associated with Alendronate Sodium NDC 33261-993 by Aidarex Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
chemical structure - alendronate 35 mg for teva 1
IMAGE LABEL - alendronate 35 mg for teva 10
This is a medication packaging for Alendronate 35mg. The label indicates that the medication should not be dispensed without a prescription and should be kept out of reach of children. It should be stored at a controlled room temperature between 16-30 degrees Celsius (53-86 degrees Fahrenheit). The medication is manufactured by Aidarex Pharmaceuticals LLC and is a generic version of Fosamax. The active ingredient is Alendronate Sodium, and it is to be taken every 24 hours, once a day. The packaging contains four pills and the manufacturer is TEVA Pharmaceuticals USA, located in Sellersville, PA 18960.*
figure 1 - alendronate 35 mg for teva 2
figure 2 - alendronate 35 mg for teva 3
Figure 3 (Top) - alendronate 35 mg for teva 4
Figure 3 (Bottom) - alendronate 35 mg for teva 5
Figure 4 (Top) - alendronate 35 mg for teva 6
This text provides a chart showing the mean % change in bone mineral density (BMD) from baseline after a 2-year study of alendronate and placebo treatments. The chart includes measurements for the lumbar spine, femoral neck, trochanter, and total body.*
Figure 4 (Bottom) - alendronate 35 mg for teva 7
Figure 5 - alendronate 35 mg for teva 8
Figure 6 - alendronate 35 mg for teva 9
This is data on the mean percentage change from baseline of Senum Alkaline Phosphatase for different treatments over time (in months). The treatments include placebo, Eidronate at 400 mg/day, Multinational Study Aendronas at 40 mg/day, and US Study A Hendronate at 40 mg/day. However, there is not enough information to draw any conclusions from the data presented.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
